NCT06504719Completed
Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan
Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients With Advanced Breast Cancer
Source: ClinicalTrials.gov · Last updated 15 Sept 2025
Brief summary (registry, in English)
The study aims to evaluate real-world efficacy and toxicity data of treatment with Trastuzumab deruxtecan (T-DXd), a HER2-targeting ADC and sacituzumab govitecan (SG), a TROP-2-targeting ADC in pretreated patients with advanced breast cancer.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 312 (actual)
- First submitted
- 9 Apr 2024
- Start date
- 1 Jan 2023
- Primary completion date
- 1 Jun 2024
- Lead sponsor
- Hellenic Cooperative Oncology Group
- Diseases
- Metastatic breast cancer
- NCT number
- NCT06504719
What you commit to
- Study type: Observational
- Participants enrolled: 312
- From 1 Jan 2023 to the primary completion date, 1 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- NA
Who the study is looking for
- Histologically confirmed metastatic/recurrent breast cancer
- 18 years of age
- Triple-negative (TNBC), HER2-positive and/or hormone receptor positive advanced breast cancer
- Treatment with an ADC at any of line of treatment
- Treatment with at least one cycle of T-DXd and/or SG
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hellenic Cooperative Oncology Group Coordinator of this site? Confirm its status | Athens | Greece | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.